Protagonist Therapeutics, Inc. EPS (Earnings per Share) 2014–2025
Protagonist Therapeutics, Inc. reported $-2.05 of earnings per share for fiscal 2025. That was 148.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -6.8%.
| Fiscal year | EPS (Earnings per Share) | Change (YoY) |
|---|---|---|
| FY 2025 | $-2.05 | -148.5% |
| FY 2024 | $4.23 | +404.3% |
| FY 2023 | $-1.39 | +46.5% |
| FY 2022 | $-2.60 | +4.1% |
| FY 2021 | $-2.71 | -41.1% |
| FY 2020 | $-1.92 | — |
| FY 2019 | $0.00 | — |
| FY 2018 | $0.00 | — |
| FY 2017 | $0.00 | — |
| FY 2016 | $0.00 | — |
| FY 2015 | $0.00 | — |
| FY 2014 | $0.00 | — |
Source: Protagonist Therapeutics, Inc. SEC filings — income statement (10-K), split-adjusted. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PTGX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Protagonist Therapeutics, Inc. reported $-2.05 of earnings per share for fiscal 2025. That was 148.5% lower than fiscal 2024. Compared with fiscal 2020, the change was -6.8%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Protagonist Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeProtagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s earnings per share?
Protagonist Therapeutics, Inc. (PTGX) reported earnings per share of $-2.05 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (income statement (10-K), split-adjusted), refreshed nightly. Not investment advice.